Case Study: Immunogenicity of Factor VIII

  • Silke Ehrenforth
  • Stephanie Seremetis
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume VIII)


Factor VIII Bleeding Episode Recombinant Factor VIIa Severe Haemophilia Inhibitor Development 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abshire, T. C., Brackmann, H. H., Scharrer, I., Hoots, K., Gazengel, C., Powell, J. S., Gorina, E., Kellermann, E., and Vosburgh, E. 2000. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Thromb. Haemost. 83:811–816.PubMedGoogle Scholar
  2. Abshire, T. and Kenet, G. 2004. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J. Thromb. Haemost. 2:899–909.PubMedCrossRefGoogle Scholar
  3. Addiego, J. E. Jr., Gomperts, E., Liu, S.-L., Bailey, P., Courter, S. G., Lee, M. L., Neslund, G. G., Kingdon, H. S., and Griffith, M. J. 1992. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIII immunoaffinity chromatography. Thromb. Haemost. 67:19–27.PubMedGoogle Scholar
  4. Addiego, J. E., Kasper, C., Abildgaard, C., Hilgartner, M., Lusher, J., Glader, B., and Aledort, L. 1993. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 342:462–464.PubMedCrossRefGoogle Scholar
  5. Addiego, J. E., Kasper, C., Abildgaard, C., Lusher, J., Hilgartner, M., Glader, B., Aledort, L., Hurst, D., and Bray, G. 1994. Increased frequency of inhibitors in African American hemophilic patients. Blood 1:293a.Google Scholar
  6. Aledort, L. M. 2004. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J. Thromb. Haemost. 2:861–862.CrossRefGoogle Scholar
  7. Aledort, L. M. and DiMichele, D. M. 1998. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 4:68.PubMedCrossRefGoogle Scholar
  8. Ananyeva, N. M., Lacroix-Desmazes, S., Hauser, C. A. Shima, M., Ovanesov, M. V., Khrenov, A. V., and Saenko, E. L. 2004. Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul. Fibrinolysis 15: 109–124.PubMedCrossRefGoogle Scholar
  9. Antonarakis, S. E., Kazazian, H. H., and Tuddenham, E. G. D. 1995. Molecular etiology of factor VIII deficiency in hemophilia A. Hum. Mutat. 5:1–22.PubMedCrossRefGoogle Scholar
  10. Arkin, S., Cooper, H. A., Hutter, J. J., Miller, S., Schmidt, M. L., Seibel, N. L., Shapiro, A., and Warrier, I. 1998. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the NovoSeven emergency-use program. Haemostasis 28: 93–98.PubMedCrossRefGoogle Scholar
  11. Astermark, J. 2006. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophilia 12 (Suppl. 6):8–14.PubMedCrossRefGoogle Scholar
  12. Astermark, J., Berntorp, E., White, G. C., and Kroner, B. L. 2001. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 7:267–272.PubMedCrossRefGoogle Scholar
  13. Astermark, J., Oldenburg, J., Escobar, M., White G. C., Berntorp E., and the MIBS Study Group. 2005. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 90:924–931.PubMedGoogle Scholar
  14. Astermark, J., Oldenburg, J., Pavlova, A., Berntorp, E., Lefvert, A. K., and the MIBS Study Group. 2006. Polymorphisms in the IL-10 but not in the IL-1β and IL-4 genes are associated with inhibitor development in patients with haemophilia A. Blood 107:3167–3172.PubMedCrossRefGoogle Scholar
  15. Barr, R. D., Saleh, M., Furlong, W., Horsman, J., Sek, J., Pai, M., and Walker, I. 2002. Health status and health-related quality of life associated with hemophilia. Am. J. Hematol. 71:152–160.PubMedCrossRefGoogle Scholar
  16. Bech, R. M. 1996. Recombinant factor VIIa in joint and muscle bleeding episodes. Haemostasis 26:135–138.PubMedGoogle Scholar
  17. Behrmann, M., Pasi, J., Saint-Remy, J. M., Kotitschke, R., and Kloft, M. 2002. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb. Haemost. 88:221–229.PubMedGoogle Scholar
  18. Berntorp, E. 2003. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance? Haematologica 88:EREP03PubMedGoogle Scholar
  19. Berntorp, E., Astermark, J., Donfield, S. M., Nelson, G. W., Oldenburg, J., Shapiro, A. D., DiMichele, D. M., Ewenstein, B. M., Gomperts, E. D., Winkler, C. A., and the Hemophilia Inhibitor Genetics Study. 2005. Haemophilia Inhibitor Genetics Study – evaluation of a model for studies of complex diseases using linkage and associated methods. Haemophilia 11:427–429.Google Scholar
  20. Berntorp, E. and Lefvert, A. 2006. A bi-allelic polymorphism in the promoter region of the TNF alpha gene influences the risk of inhibitor development in patients with hemophilia A. Haemophilia 12:abstract 14FP36Google Scholar
  21. Bolton-Maggs, P. H., Stobart, K., and Smyth, R. L. 2004. Evidence-based treatment of haemophilia. Haemophilia 10 (Suppl. 4):20–24.PubMedCrossRefGoogle Scholar
  22. Brackmann, H. H., Effenberger, E., Hess, L., Schwaab, R., and Oldenburg, L. 2000. NovoSeven in immune tolerance therapy. Blood Coagul. Fibrinolysis 11 (Suppl. 1):S39–S44.PubMedGoogle Scholar
  23. Brackmann, H. H., Oldenburg, J., and Schwaab, R. 1996. Immune tolerance for the treatment of FVIII inhibitors-twenty years of the Bonn protocol, Vox Sang. 70 (Suppl. 1):30–35.Google Scholar
  24. Bray, G. L., Gomperts, E. D., Courter, S., Gruppo, R., Gordon, E. M., Manco-Johnson, M., Shaprio, A., Scheibel, E., White, G. 3rd, and Lee, M. 1994. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood 83:2428–2435.PubMedGoogle Scholar
  25. Calvez, T. and Laurian, Y. 2006. Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required. Br. J. Haematol. 132:798–799.PubMedCrossRefGoogle Scholar
  26. Chalmers, E. A., Brown, S. A., Keeling, D., Liesner, R., Richards, M., Stirling, D., Thomas, A., Vidler, V., Williams, M. D., and Young, D. on behalf of the Paediatric Working Party of UKHCDO, 2007. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 13: 149–155.PubMedCrossRefGoogle Scholar
  27. Chuansumrit, A., Sri-Udomporn, N., Srimuninnimit, V., and Juntarukha, R. 2001. A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors. Haemophilia 7: 532–534.PubMedCrossRefGoogle Scholar
  28. Cooper, H. A., Jones, C. P., Campion, E., Roberts, H. R., and Hedner, U. 2001. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 7:517–522.PubMedCrossRefGoogle Scholar
  29. Courter, S. G. and Bedrosian, C. L. 2001. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin. Hematol. 38:529.Google Scholar
  30. DiMichele, D. M. 1998. Immune tolerance: a synopsis of international experience. Haemophilia 4:568–573.CrossRefGoogle Scholar
  31. DiMichele, D. M. 2000. Inhibitors in haemophilia: a primer. Haemophilia 6 (Suppl. 1):38–40.PubMedCrossRefGoogle Scholar
  32. DiMichele, D. 2002. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 8:280–287.PubMedCrossRefGoogle Scholar
  33. Dolan, G. 2005. ESOS: A European study on the orthopaedic status of patients with haemophilia and inhibitors. Haemophilia 11 (Suppl. 1):24–25.PubMedCrossRefGoogle Scholar
  34. Ehrenforth, S., Kreuz, W., Scharrer, I., Linde, R., Funk, M., Güngör, T., Krackhardt, B., and Kornhuber, B. 1992. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594–598.PubMedCrossRefGoogle Scholar
  35. Ehrlich, H. J., Henzl, M. J., and Gomperts, E. D. 2002. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 8:83–90.PubMedCrossRefGoogle Scholar
  36. Ettingshausen, C. E., Martinez Saguer, I., Funk, M. B., Klarmann, D., Stoll, H., Biller, R., and Kreuz, W. 2003. Long-term prophylaxis with FEIBA in patients with high-responding inhibitors. J. Thromb. Haemost. 1 (Suppl. 1):abstract P1628.Google Scholar
  37. Ettingshausen, C. E. and Kreuz, W. 2005. Role of von Willebrand factor in immune tolerance induction. Blood Coagul. Fibrinolysis 16 (Suppl. 1):S27–S31.PubMedCrossRefGoogle Scholar
  38. Ettingshausen, C. E. and Kreuz, W. 2006. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 12 (Suppl. 6):102–106.PubMedCrossRefGoogle Scholar
  39. Fay, P. J. 2004. Activation of factor VIII and mechanisms of cofactor action. Blood Rev. 18:1–15.PubMedCrossRefGoogle Scholar
  40. Fay, P. J., Anderson, M. T., Chavin, S. I., and Marder, V. J. 1986. The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim. Biophys. Acta 871:268–278.Google Scholar
  41. Fay, P. J., Beattie, T. L., Regan, L. M., O’Brien, L. M., and Kaufman, R. J. 1996. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase: role of subunit dissociation and factor IXa-catalyzed proteolysis. J. Biol. Chem. 271: 6027–6032.PubMedCrossRefGoogle Scholar
  42. Federici, A. B. 2003. The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica 88:EREP02PubMedGoogle Scholar
  43. Fontes, E., Carvalho, S., and Amorim, L. 2004. Age at the beginning of factor VIII replacement is not a risk factor for inhibitor development in hemophilia A. Haemophilia 10:55 abstract 12 OC 14.CrossRefGoogle Scholar
  44. Frommel, D., and Allain, J. P. 1977. Genetic predisposition to develop factor VIII antibody in classic hemophilia. Clin. Immunol. Immunopathol. 8:34–38.PubMedCrossRefGoogle Scholar
  45. Frommel, D., Allain, J. P., Saint-Paul, E., Bosser, C., Noël, B., Mannucci, P. M., Pannicucci, F., Blombäck, M., Prou-Wartelle, O., and Muller, J. Y. 1981. HLA antigens and factor VIII antibody in classic hemophilia. European study group of factor VIII antibody. Thromb. Haemost. 46:687–689.Google Scholar
  46. Fulcher, C. A., de Graaf Mahoney, S., and Zimmerman, T. S. 1987. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 69:1475–1480.PubMedGoogle Scholar
  47. Gill, J. C. 1999. The role of genetics in inhibitor formation. Thromb. Haemost. 82:500–504.PubMedGoogle Scholar
  48. Gilles, J. G., Arnout, J., Vermylen, J., and Saint-Remy, J. M. 1993. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 82:2452–2461.PubMedGoogle Scholar
  49. Goodeve, A. C., and Peake, I. R. 2003. The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Seminars in Thrombosis and Hemostasis, 29:23–30.Google Scholar
  50. Goodeve, A. C., Williams, I., Bray, G. L., and Peake, I. R. 2000. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (recombinate). Recombinate PUP Study Group. Thromb. Haemost. 83:844–848.Google Scholar
  51. Goudemand, J., Rothschild, C., Demiguel, V., Vinciguerrat, C., Lambert, T., Chambost, H., Borel-Derlon, A., Claeyssens, S., Laurian, Y., and Calvez, T. 2006. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. Blood 107:46–51.PubMedCrossRefGoogle Scholar
  52. Gouw, S. C., van der Bom, J. G., and van den Berg, H. M. 2007. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL Cohort Study. Blood 109:4693–4697.PubMedCrossRefGoogle Scholar
  53. Green, D. 1999. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 5 (Suppl. 3):11–17.PubMedCrossRefGoogle Scholar
  54. Gringeri, A., Mantovani, L., Scalone, L., Mannucci, P. M., and the COCIS Study Group. 2003. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 102:2358–2363.Google Scholar
  55. Gringeri, A., Monzini, M., Tagariello, G., Scaraggi, F. A., Mannucci, P. M., and the Emoclot 15 Study Members. 2006. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia 12:128–132.Google Scholar
  56. Hay, C. R. M. 2002. The 2000 United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) inhibitor guidelines. Pathophysiol Haemost Thromb 32 (Suppl. 1):19–21.PubMedCrossRefGoogle Scholar
  57. Hay, C. R. M. 2006. The epidemiology of factor VIII inhibitors. Haemophilia 12 (Suppl. 6):23–29.PubMedCrossRefGoogle Scholar
  58. Hay, C. R., Ludlam, C. A., Colvin, B. T., Hill, F. G., Preston, F. E., Wasseem, N., Bagnall, R., Peake, I. R., Berntorp, E., Mauser Bunschoten, E. P., Fijnvandraat, K., Kasper, C. K., White, G., and Santagostino, E. 1998. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb. Haemost. 79:762–766.Google Scholar
  59. Hay, C. R., Ollier, W., Pepper, L. Cumming, A., Keeney, S., Goodeve, A. C., Colvin, B. T., Hill, F. G., Preston, F. E., and Peake, I. R. 1997. HLA class II profile: A weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb. Haemost. 77:234–237.Google Scholar
  60. Hedner, U. 2003. Potential role of recombinant factor VIIa as a hemostatic agent. Clin. Adv. Hematol. Oncol. 1:112–119.PubMedGoogle Scholar
  61. Hedner, U., Glazer, S., Pingel, K. Alberts, K. A., Blombäck, M., Schulman, S., and Johnsson, H. 1988. Successful use of recombinant factor VIIa in patient with severe hemophilia A during synovectomy. Lancet 2:1193.PubMedCrossRefGoogle Scholar
  62. Hilgartner, M., Aledort, L., Andes, A., and Gill, J. 1990. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 30:626–630.Google Scholar
  63. Hilgartner, M., Knatterud, G. L. and the FEIBA Study Group. 1983. The use of factor VIII by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitor. Blood 61:36–40.PubMedGoogle Scholar
  64. Hilgartner, W., Makipernaa, A., and DiMichele, D. M. 2003. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 9:261–268.PubMedCrossRefGoogle Scholar
  65. Hodge, G., Flower, R., and Han, P. 1999. Effect of factor VIII concentrate on leucocyte cytokine production: characterisation of TGF-beta as an immunomodulatory component in plasma derived factor VIII concentrate. Br. J. Haematol. 106:784–791.PubMedCrossRefGoogle Scholar
  66. Hodge, G., Saxon, B., and Revesz, T. 2006. Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction. Haemophilia 12:133–139.PubMedCrossRefGoogle Scholar
  67. Hoffman, M., Monroe, D. M. III, and Roberts, H. R. 1998. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul. Fibrinolysis 9 (Suppl. 1):S61–S65.PubMedGoogle Scholar
  68. Hoots, W. K. 2006. Urgent inhibitor issues: targets for expanded research. Haemophilia 12:107–113.PubMedCrossRefGoogle Scholar
  69. Ingerslev, J., Freidman, D., Gastineau, D., Gilchrist, G., Johnsson, H., Lucas, G., McPherson, J., Preston, E., Scheibel, E., and Shuman, M. 1996. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 26 (Suppl. 1):118–123.PubMedGoogle Scholar
  70. Ingerslev, J., Knudsen, L., Hvid, I., Tange, M. R., Fredberg, U., and Sneppen, O. 1997. Use of recombinant factor VIIa in surgery in factor VII deficient patients. Haemophilia 3:215–218.CrossRefGoogle Scholar
  71. Johannessen, M., Andreasen, R., and Nordfang, O. 2000. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven. Blood Coagul. Fbrinolysis 11:239–242.Google Scholar
  72. Jurlander, B., Thim, L., Klausen, N. K., Persson, E., Kjalke, M., Rexen, P., Jorgensen, T. B., Ostergaard, P. B., Erhardtsen, E., and Bjorn, S. E. 2001. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin. Thromb. Hemost. 27:373–384.PubMedCrossRefGoogle Scholar
  73. Kasper, C. K., Aledort, L., Aronson, D., Counts, R., Edson, J. R., van Eys, J., Fratantoni, J., Green, D., Hampton, J., Hilgartner, M., Levine, P., Lazerson, J., McMillan, C., Penner, J., Shapiro, S, and Shulman, N. R. 1975. A more uniform measurement of factor VIII inhibitors. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb. Diath. Haemorrh. 34:612.Google Scholar
  74. Kaufman, R. J. and Pipe, S. W. 1999. Regulation of factor VIII expression and activity by von Willebrand factor. Thromb. Haemost. 82:201–208.PubMedGoogle Scholar
  75. Kavakli, K., Makris, M., Zulfikar, B., Abrams, Z., and Kenet, G. 2006. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb. Haemost. 95:600–605.Google Scholar
  76. Kenet, G., Lubetsky, A., Luboshitz, J., and Martinowitz, U. 2003. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J. Thromb. Haemost. 1:450–455.PubMedCrossRefGoogle Scholar
  77. Kessler, C. M. 2005. New perspectives in hemophilia treatment. Hematology (Am. Soc. Hematol. Educ. Program) 1:429–435.Google Scholar
  78. Key, N. S. 2004. Inhibitors in congenital coagulation disorders. Br. J. Haematol. 127:379–391.PubMedCrossRefGoogle Scholar
  79. Key, N. S., Aledort, L. M., Beardsley, D., Cooper, H. A., Davignon, G., Ewenstein, B. M., Gilchrist, G. S., Gill, J. C., Glader, B., Hoots, W. K., Kisker, C. T., Lusher, J. M., Rosenfield, C. G., Shapiro, A. D., Smith, H., and Taft, E. 1998. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb. Haemost. 80:912–918.PubMedGoogle Scholar
  80. Konkle, B. A., Ebbesen, L. S., Auerswald, G. K. H., Friedrich, U., Ljung, R. C. R., Roberts, H. R., and Hoots, W. K. 2006a. Secondary prophylaxis with rFVIIa improves quality of life of hemophilia patients with inhibitors and frequent bleeds. Abstract presented during the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH), Orlando, Florida, USA, 9–12 December 2006 (abstract no. 766).Google Scholar
  81. Konkle, B. A., Ebbesen, L. S., Friedrich, U., Bianco, R. P., Lissitchkov, T., Rusen, L., Serban, M. A. and the NovoSeven (F7Haem-1505) Investigators. 2006b. Randomized, prospective clinical trial of rFVIIa for secondary prophylaxis in hemophilia patients with inhibitors. Data presented during the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH), Orlando, Florida, USA, 9–12 December 2006 (abstract no. 1028).Google Scholar
  82. Kreuz, W., Ettingshausen, C. E., Auerswald, G., Saguer, I. M., Becker, S., Funk, M., Heller, C., Klarmann, D., Klingebiel, T., and the GTH PUP Study Group. 2003. Epidemiology of inhibitors and current treatment strategies. Haematologica 88:EREP04.Google Scholar
  83. Kreuz, W., Auerswald, G., Budde, U., Lenk, H., and the GTH-PUP-Study Group. 2005a. In: I. Scharrer and W. Schramm, Editors, Inhibitor development in previously untreated patients (PUPs) with haemophilia A and B. A prospective multicentre study of the German, Swiss and Austrian Society of Thrombosis and Haemostasis Research (GTH). 35th Haemophilia Symposium, Springer Verlag, Hamburg 2004, 34–37.Google Scholar
  84. Kreuz, W., Gill, J. C., Rothschild, C., Manco-Johnson, M. J., Lusher, J. M., Kellermann, E., Gorina, E., Larson, P. J., and the International Kogenate-FS Study Group. 2005b. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A. Results of an international clinical investigation. Thromb. Haemost. 93:457–467.Google Scholar
  85. Leissinger, C. A. 2004. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am. J. Hematol. 77:187–193.PubMedCrossRefGoogle Scholar
  86. Lenting, P., Neels, J., van den Berg, B., Clijsters, P. P., Meijerman, D. W., Pannekoek, H., van Mourik, J. A., Mertens, K., and van Zonneveld, A. J. 1999. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J. Biol. Chem. 274:23734–23739.PubMedCrossRefGoogle Scholar
  87. Levi, M., Peters, M., and Buller, H. R. 2005. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit. Care Med. 33:883–890.PubMedCrossRefGoogle Scholar
  88. Lin, Y., Yang, X., Chevrier, M. C. Craven, S., Barrowcliffe, T. W., Lemieux, R., and Ofosu, F. A. 2004. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma derived factor VIII concentrates. Haemophilia 10:459–469.PubMedCrossRefGoogle Scholar
  89. Lollar, P. 1991. The association of factor VIII with von Willebrand factor. Mayo Clin. Proc. 66:524–534.PubMedGoogle Scholar
  90. Lorenzo, J. I., Lopez, A., Altisent, C., and Aznar, J. A. 2001. Incidence of factor VIII inhibitors in severe haemophilia: the importance of age. Br. J. Haematol. 113:600–603.PubMedCrossRefGoogle Scholar
  91. Lusher, J. M. 1991. Thrombogenicity associated with factor IX complex concentrates. Semin. Hematol. 28 (3 Suppl. 6):3–5.PubMedGoogle Scholar
  92. Lusher, J. M. 1996. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 26:124–130.PubMedGoogle Scholar
  93. Lusher, J. M. 2000. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul. Fibrinolysis 11 (Suppl. 1): S45–S49.PubMedGoogle Scholar
  94. Lusher, J. M. 2004. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J. Thromb. Haemost. 2:863–865.CrossRefGoogle Scholar
  95. Lusher, J. M., Arkin, S., Abildgaard, C. F., and Schwartz, R. S. 1993. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A – safety, efficacy, and development of inhibitors. N. Engl. J. Med. 328:453–459.PubMedCrossRefGoogle Scholar
  96. Lusher, J., Ingerslev, J., Roberts, H., and Hedner, U. 1998. Clinical experience with recombinant factor VIIa. Blood Coagul. Fibrinol. 9:119–128.CrossRefGoogle Scholar
  97. Lusher, J. M., Lee, C. A., Kessler, C. M., Bedrosian, C. L., and the ReFacto Phase 3 Study Group. 2003. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 9:38–49.Google Scholar
  98. Lusher, J. M., Roberts, H. R., Davignon, G., Joist, J. H., Smith, H., Shapiro, A., Laurian, Y., Kasper, C. K., and Mannucci, P. M. 1998. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 4:790–798.PubMedCrossRefGoogle Scholar
  99. Lusher, J. M. and Roth, D. A. 2005. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update. Haemophilia 11:292–293.PubMedCrossRefGoogle Scholar
  100. Lusher, J. M., Shapiro, S. S., Palascak, J. E., Rao, A. V., Levine, P. H., and Blatt, P. M. 1980. Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N. Engl. J. Med. 303: 421–425.PubMedCrossRefGoogle Scholar
  101. Luu, H. and Ewenstein, B. 2004. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 10 (Suppl. 2):10–16.PubMedCrossRefGoogle Scholar
  102. Mann, K. G. 1999. Biochemistry and physiology of blood coagulation. Thromb. Haemost. 82:165–174.PubMedGoogle Scholar
  103. Mariani, G. and Kroner, B. L. 1999. International Immunetolerance Registry 1997 update. Vox Sang. 77:25–27.PubMedCrossRefGoogle Scholar
  104. MASAC Recommendation #177, revised October 2006. Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation. Recommendations concerning the treatment of hemophilia and other bleeding disorders ( Scholar
  105. McMillan, C. W., Shapiro, S. S., Whitehurst, D., Hoyer, L. W., Rao, A. V., and Lazerson, J. 1988. The natural history of factor VIII: C inhibitors in patients with hemophilia A: a National Cooperative Study. II. Observations on the initial development of factor VIII: C inhibitors. Blood 71:344–348.PubMedGoogle Scholar
  106. Morado, M., Villar, A., Jimenez-Yuste, V., Quintana, M., and Hernandez Navarro, F. 2005. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 11:79–83.PubMedCrossRefGoogle Scholar
  107. Morrison, A. E., Ludlam, C. A., and Kessler, C. 1993. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 81:1513–1520.PubMedGoogle Scholar
  108. Negrier, C., Goudemand, J., Sultan, Y., Bertrand, M., Rothschild, C., and Lauroua, P. 1997. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. factor eight bypassing activity. Thromb. Haemost. 77:1113–1119.Google Scholar
  109. Nicolaisen, E. M. 1996. Clinical experience with NovoSeven: lack of antigenicity after repeated treatment with NovoSeven. Haemostasis 26 (Suppl. 1):98–101.PubMedGoogle Scholar
  110. O’Connell, N., Mc Mahon, C., Smith, J., Khair, K., Hann, I., Liesner, R., and Smith O. P. 2002. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors. Br. J. Haematol. 116:632–635.PubMedCrossRefGoogle Scholar
  111. Oldenburg, J., El-Maarri, O., and Schwaab, R. 2002. Inhibitor development in correlation to factor VIII genotypes. Haemophilia, 8 (Suppl. 2):23–29.PubMedCrossRefGoogle Scholar
  112. Oldenburg, J. and Pavlova, A. 2006. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 12 (Suppl. 6):15–22.PubMedCrossRefGoogle Scholar
  113. Oldenburg, J., Picard, J. K., Schwaab, R. Brackmann, H. H., Tuddenham, E. G., and Simpson, E. 1997. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb. Haemost. 77:238–242.PubMedGoogle Scholar
  114. Oldenburg, J., Schroder, J., Brackmann, H. H., Müller-Reible, C., Schwaab, R., Tuddenham, E. 2004. Environmental and genetic factors influencing inhibitor development. Semin. Hematol. 41 (Suppl. 1):82–88.PubMedCrossRefGoogle Scholar
  115. Oldenburg, J., and Tuddenham, E. 2002. Genetic basis of inhibitor development in severe haemophilia A and B. In: E. C. Rodriguez-Merchan and C. A. Lee, Editors, Inhibitors in patients with haemophilia, Blackwell Publishing, Oxford, pp. 21–26.CrossRefGoogle Scholar
  116. Parameswaran, R., Shapiro, A. D., Gill, J. C., Kessler, C. M., and the HTRS Registry Investigators. 2005. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 11:100–106.PubMedCrossRefGoogle Scholar
  117. Peerlinck, K. and Hermans, C. 2006. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 12:579–590.PubMedCrossRefGoogle Scholar
  118. Pittman, D. D., Alderman, E. M., Tomkinson, K. N., Wang, J. H., Giles, A. R., and Kaufman, R. J. 1993. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 81:2925–2935.PubMedGoogle Scholar
  119. Quintana-Molina, M., Martinez-Bahamonde, F., Gonzalez, G., Romero-Garrido, J., Villar-Camacho, A., Jiménez-Yuste, V., Fernández-Bello, I., and Hernández-Navarro, F. 2004. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 10 (Suppl. 2): 30–40.PubMedCrossRefGoogle Scholar
  120. Roberts, H. R., Monroe, D. M. III, and Hoffman, M. 2004. Safety profile of recombinant factor VIIa. Semin. Hematol. 41 (Suppl. 1):101–108.Google Scholar
  121. Rokicka-Milewska, R., Klukowska, A., Dreger, B., and Beer, H. J. 1999. Incidence of factor VIII inhibitor development in previously untreated hemophilia A patients after exposure to a double viral inactivated factor VIII concentrate. Ann. Hematol. 78 (Suppl. 1):1–7.Google Scholar
  122. Rothschild, C., Gill, J., Scharrer, I., and Bray, G. 2000. Transient inhibitors in the Recombinate PUP Study. Thromb. Haemost. 84:145–146.PubMedGoogle Scholar
  123. Saenko, E. L, Ananyeva, N., Kouiavskaia, D., Schwinn, H., Josic, D., Shima, M., Hauser, C.A., and Pipe, S. 2002. Molecular defects in coagulation factor VIII and their impact on factor VIII function. Vox Sang. 83:89–96.PubMedCrossRefGoogle Scholar
  124. Sandberg, H., Almstedt, A., Brandt, J., Gray, E., Holmquist, L., Oswaldsson, U., Sebring, S., and Mikaelsson, M. 2001. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb. Haemost. 85:93–100.PubMedGoogle Scholar
  125. Santagostino, E., Gringeri, A., and Mannucci, P. M. 1999. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br. J. Haematol. 104:22–26.PubMedCrossRefGoogle Scholar
  126. Santagostino, E., Mancuso, M. E., Rocino, A., Mancuso, G., Mazzucconi, M. G., Tagliaferri, A., Messina, M., and Mannucci, P. M. 2005. Environmental risk factors for inhibitor development in children with haemophilia A: a Case-Control Study. Br. J. Haematol. 130:422–427.PubMedCrossRefGoogle Scholar
  127. Santagostino, E., Mancuso, M. E., Rocino, A., Mancuso, G., Scaragg, F., and Mannucci, P. M. 2006. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J. Thromb. Haemost. 4:367–371.PubMedCrossRefGoogle Scholar
  128. Santagostino, E. and Mannucci, P. M. 2006. Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required. Response to Calvez and Laurian. Br. J. Haematol. 132:800–801.CrossRefGoogle Scholar
  129. Santagostino, E., Morfini, M., Rocino, A., Baudo, F, Scaraggi, F. A., and Gringeri, A. 2001. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb. Haemost. 86:954–958.PubMedGoogle Scholar
  130. Scharrer, I., Bray, G. L., and Neutzling, O. 1999. Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 5:145–154.PubMedCrossRefGoogle Scholar
  131. Scharrer, I. and Ehrlich, H. J. 2004. Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges? Haemophilia 10:197–198.PubMedCrossRefGoogle Scholar
  132. Schwaab, R., Brackmann, H. H., Meyer, C., Seehafer, J., Kirchgesser, M., Haack, A., Olek, K., Tuddenham, E. G., and Oldenburg, J. 1995. Haemophilia A: mutation type determinates risk of inhibitor formation. Thromb. Haemost. 74:1402–1406.PubMedGoogle Scholar
  133. Schwartz, R. S., Abildgaard, C. F., Aledort, L. M., Arkin, S., Bloom, A. L., Brackmann, H. H., Brettler, D. B., Fukui, H., Hilgartner, M. W., Inwood, M. J., et al. 1990. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. N. Engl. J. Med. 323:1800–1805.PubMedCrossRefGoogle Scholar
  134. Schwartz, H. P., Lenting, P. J., Binder, B., Mihaly, J., Denis, C., Dorner, F., and Turecek, P. L. 2000. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood 95:1703–1708.Google Scholar
  135. Seremetis, S., Lusher, J. M., Abildgaard, C. F., Kasper, C. K., Allred, R., and Hurst, D. 1999. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. Haemophilia 5:9–16.PubMedCrossRefGoogle Scholar
  136. Shapiro, S. S. 1984. Genetic predisposition to inhibitor formation. Prog. Clin. Biol. Res. 150:45–55.PubMedGoogle Scholar
  137. Shapiro, A. D., Gilchrist, G. S., Hoots, W. K., Cooper, H. A., and Gastineau, D. A. 1998. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb. Haemost. 80:773–778.PubMedGoogle Scholar
  138. Sharathkumar, A., Lillicrap, D., Blanchette, V. S., Kern, M., Leggo, J., Stain, A. M., Brooker, L, and Carcao, M. D. 2003. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild haemophilia A. J. Thromb. Haemost. 1:1228–1236.PubMedCrossRefGoogle Scholar
  139. Smith, O. P. 2002. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors. Pathophysiol. Haemost. Thromb. 32 (Suppl. 1):22–25.CrossRefGoogle Scholar
  140. Smith, O. P. and Hann, I. M. 1996. RFVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors. Br. J. Haematol. 92:1002–1004.PubMedCrossRefGoogle Scholar
  141. Sultan, Y. 1992. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb. Haemost. 67: 600–602.Google Scholar
  142. Syamsoedin, L. J., Heijnen, L., Mauser-Bunschoten, E. P. van Geijlswijk J. L., van Houwelingen, H., van Asten, P., and Sixma, J. J. 1981. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N. Engl. J. Med. 305:717–721.Google Scholar
  143. Tarantino, M. D., Collins, P. W., Hay, C. R., Shapiro, A. D., Gruppo, R. A., Berntorp, E., Bray, G. L., Tonetta, S. A., Schroth, P. C., Retzios, A. D., Rogy, S. S., Sensel, M. G., Ewenstein, B. M., and the RAHF-PFM Clinical Study Group. 2004. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 10:428–437.Google Scholar
  144. Toole, J. J., Pittman, D. D., Orr, E. C., Murtha, P., Wasley, L. C., and Kaufman, R. J. 1986. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad. Sci. USA 83: 5939–5942.PubMedCrossRefGoogle Scholar
  145. Triemstra, M., Rosendaal, F. R., Smit, C., van der Ploeg, H. M., and Briët, E. 1995. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann. Intern. Med. 123:823–827.Google Scholar
  146. Turecek, P. L., Varadi, K., Gritsch, H., and Schwarz, H. P. 2004. FEIBA: mode of action. Haemophilia 10 (Suppl. 2):3–9.PubMedCrossRefGoogle Scholar
  147. UK Haemophilia Centre Doctors’ Organisation. 2004. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J. Thromb. Haemost. 2:1047–1054.Google Scholar
  148. Van der Bom, J. G., Mauser-Bunschoten, E. P., Fischer, K., and van den Berg, H. M. 2003. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb. Haemost. 89:475–479.PubMedGoogle Scholar
  149. Vehar, G. A., Keyt, B., Eaton, D., Rodriguez, H., O’Brien, D. P., Rotblat, F., Oppermann, H., Keck, R., Wood, W. I., Harkins, R. N., Tuddenham, E. G. D., Lawn, R. M., and Capon, D. J. 1984. Structure of human factor VIII. Nature 312: 337–340.PubMedCrossRefGoogle Scholar
  150. Vlot, A. J., Koppelman, S. J., Bouma, B. N., and Sixma, J. J. 1998. Factor VIII and von Willebrand factor. Thromb. Haemost. 79:456–465.PubMedGoogle Scholar
  151. Von Auer, C., Oldenburg, J., Von Depka, M., Escuriola-Ettinghausen, C., Kurnik, K., Lenk, H., and Scharrer, I. 2005. Inhibitor development in patients with hemophilia A after continuous infusion of factor VIII concentrates. Ann. NY Acad. Sci. 1051: 498–505.CrossRefGoogle Scholar
  152. White, G. C. II, Courter, S., Bray, G. L., Lee, M., and Gomperts, E. D. 1997. A multicenter study of recombinant factor VIII (RecombinateTM) in previously treated patients with hemophilia A. Thromb. Haemost. 77:660–667.PubMedGoogle Scholar
  153. White, G. C. II, Rosendaal, F. R., Aledort, L. M., Lusher, J. M., Rothschild, C., Ingerslev, J., and the Factor VIII and Factor IX Subcommittee. 2001. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thromb Haemostas. Thromb. Haemost. 85:560.Google Scholar
  154. Wight, J. and Paisley, S. 2003. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9:418–435.vvsp-2PubMedCrossRefGoogle Scholar
  155. Wight, J., Paisley, S., and Knight, C. 2003. Immune tolerance induction in patients with hemophilia A with inhibitors: a systematic review. Haemophilia 9:436–463.PubMedCrossRefGoogle Scholar
  156. Yee, T. T., Williams, M. D., Hill, F. G., Lee, C. A., and Pasi, K. J. 1997. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product. Thromb. Haemost. 78: 1027–1029.PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2008

Authors and Affiliations

  • Silke Ehrenforth
  • Stephanie Seremetis

There are no affiliations available

Personalised recommendations